

| | | | | |
|---|-----|---|--------------------------------|--|
| FORM PTO-1449/A and B (modified PTO/SB/08) | | | APPLICATION NO.: 10/023,909 | ATTY. DOCKET NO.: C1039.70058US00 |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT | | | FILING DATE: December 18, 2001 | CONFIRMATION NO.: 8458 |
| | | | APPLICANT: Davis et al. | |
| O Sheet | 103 | 1 | of 12 | GROUP ART UNIT: 1648 EXAMINER: Jeffrey S. Parkin |

OCT 22 2007
U.S. PATENT AND TRADEMARK OFFICE

U.S. PATENT DOCUMENTS


| B. Examiner's Initials | Cite No. | U.S. Patent Document | | Name of Patentee or Applicant of Cited Document | Date of Publication or Issue of Cited Document MM-DD-YYYY |
|------------------------|----------|----------------------|-----------|---|---|
| | | Number | Kind Code | | |
| J | A109 | 5,075,109 | | Tice et al. | 12-24-1991 |
| | A110 | 5,543,152 | | Webb et al. | 08-06-1996 |
| | A111 | 5,595,756 | | Bally et al. | 01-21-1997 |
| | A112 | 5,663,153 | | Hutcherson et al. | 09-02-1997 |
| | A113 | 5,679,647 | | Carson et al. | 10-21-1997 |
| | A114 | 5,705,385 | | Bally et al. | 01-06-1998 |
| | A115 | 5,723,335 | | Hutcherson et al. | 03-03-1998 |
| | A116 | 5,736,152 | | Dunn | 04-07-1998 |
| | A117 | 5,753,613 | | Ansell et al. | 05-19-1998 |
| | A118 | 5,766,920 | | Babbitt et al. | 06-16-1998 |
| | A119 | 5,780,448 | | Davis | 07-14-1998 |
| | A120 | 5,814,335 | | Webb et al. | 09-29-1998 |
| | A121 | 5,965,542 | | Wasan et al. | 10-12-1999 |
| | A122 | 5,976,567 | | Wheeler et al. | 11-02-1999 |
| | A123 | 5,981,501 | | Wheeler et al. | 11-09-1999 |
| | A124 | 6,004,534 | | Langer et al. | 12-21-1999 |
| | A125 | 6,027,726 | | Ansell | 02-22-2000 |
| | A126 | 6,030,954 | | Wu et al. | 02-29-2000 |
| | A127 | 6,042,838 | | Briles et al. | 03-28-2000 |
| | A128 | 6,086,898 | | DeKruyff et al. | 07-11-2000 |
| | A129 | 6,090,791 | | Sato et al. | 07-18-2000 |
| | A130 | 6,110,745 | | Zhang et al. | 08-29-2000 |
| | A131 | 6,221,882 | B1 | Macfarlane | 04-24-2001 |
| | A132 | 6,225,292 | B1 | Raz et al. | 05-01-2001 |
| | A133 | 6,248,720 | B1 | Mathiowitz et al. | 06-19-2001 |
| | A134 | 6,399,630 | B1 | Macfarlane | 06-04-2002 |
| | A135 | 6,479,504 | B1 | Macfarlane et al. | 11-12-2002 |
| | A136 | 6,498,148 | B1 | Raz | 12-24-2002 |
| | A137 | 6,521,637 | B2 | Macfarlane | 02-18-2003 |
| | A138 | 6,610,308 | B1 | Haensler | 08-26-2003 |
| | A139 | 6,620,805 | B1 | Takle et al. | 09-16-2003 |
| | A140 | 6,693,086 | B1 | Dow et al. | 02-17-2004 |

| | |
|---|------------------|
| EXAMINER: | DATE CONSIDERED: |
|  | 12/26/07 |

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

| | | | | | |
|--|---|----|----|--------------------------------|-----------------------------------|
| FORM PTO-1449/A and B (modified PTO/SB/08) | | | | APPLICATION NO.: 10/023,909 | ATTY. DOCKET NO.: C1039.70058US00 |
| | | | | FILING DATE: December 18, 2001 | CONFIRMATION NO.: 8458 |
| | | | | APPLICANT: Davis et al. | |
| Sheet | 2 | of | 12 | GROUP ART UNIT: 1648 | EXAMINER: Jeffrey S. Parkin |

| | | | | | |
|---|------|--------------|----|------------------|------------|
| | A141 | 6,737,066 | B1 | Moss | 05-18-2004 |
| | A142 | 6,821,957 | B1 | Krieg et al. | 11-23-2004 |
| | A143 | 6,835,395 | B1 | Semple et al. | 12-28-2004 |
| | A144 | 6,893,821 | B2 | Raz et al. | 05-17-2005 |
| | A145 | 6,943,240 | B2 | Bauer et al. | 09-13-2005 |
| | A146 | 6,949,520 | B1 | Hartmann et al. | 09-27-2005 |
| | A147 | 7,001,890 | B1 | Wagner et al. | 02-21-2006 |
| | A148 | 7,049,302 | B1 | Kensil | 05-23-2006 |
| | A149 | 7,129,222 | B2 | Van Nest et al. | 10-31-2006 |
| | A150 | 7,223,741 | B2 | Krieg | 05-29-2007 |
| | A151 | 2001-0034330 | A1 | Kensil | 10-25-2001 |
| | A152 | 2002-0009457 | A1 | Bowersock et al. | 01-24-2002 |
| | A153 | 2003-0078223 | A1 | Raz et al. | 04-24-2003 |
| | A154 | 2003-0092663 | A1 | Raz et al. | 05-15-2003 |
| | A155 | 2003-0104044 | A1 | Semple et al. | 06-05-2003 |
| | A156 | 2003-0119774 | A1 | Foldvari et al. | 06-26-2003 |
| | A157 | 2003-0165478 | A1 | Sokoll et al. | 09-04-2003 |
| | A158 | 2003-0232856 | A1 | Macfarlane | 12-18-2003 |
| | A159 | 2004-0013688 | A1 | Wise et al. | 01-22-2004 |
| | A160 | 2004-0006010 | A1 | Carson et al. | 01-08-2004 |
| | A161 | 2004-0047869 | A1 | Garcon et al. | 03-11-2004 |
| | A162 | 2004-0067902 | A9 | Bratzler et al. | 04-08-2004 |
| | A163 | 2004-0092468 | A1 | Schwartz et al. | 05-13-2004 |
| | A164 | 2004-0198680 | A1 | Krieg | 10-07-2004 |
| | A165 | 2004-0229835 | A1 | Krieg et al. | 11-18-2004 |
| | A166 | 2004-0234512 | A1 | Wagner et al. | 11-25-2004 |
| | A167 | 2004-0235770 | A1 | Davis et al. | 11-25-2004 |
| | A168 | 2004-0235774 | A1 | Bratzler et al. | 11-25-2004 |
| | A169 | 2004-0235777 | A1 | Wagner et al. | 11-25-2004 |
| | A170 | 2004-0235778 | A1 | Wagner et al. | 11-25-2004 |
| | A171 | 2004-0247662 | A1 | Dow et al. | 12-09-2004 |
| | A172 | 2004-0266719 | A1 | McCluskie et al. | 12-30-2004 |
| | A173 | 2005-0004061 | A1 | Krieg et al. | 01-06-2005 |
| | A174 | 2005-0004062 | A1 | Krieg et al. | 01-06-2005 |
| | A175 | 2005-0009774 | A1 | Krieg et al. | 01-13-2005 |
| ↓ | A176 | 2005-0013812 | A1 | Dow et al. | 01-20-2005 |

| | |
|---|------------------|
| EXAMINER: | DATE CONSIDERED: |
|  | 12/24/07 |

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

| | | | | | |
|---|---|----|----|--------------------------------|-----------------------------------|
| FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT | | | | APPLICATION NO.: 10/023,909 | ATTY. DOCKET NO.: C1039.70058US00 |
| | | | | FILING DATE: December 18, 2001 | CONFIRMATION NO.: 8458 |
| | | | | APPLICANT: Davis et al. | |
| | | | | GROUP ART UNIT: 1648 | EXAMINER: Jeffrey S. Parkin |
| Sheet | 3 | of | 12 | | |

| | | | | |
|--------|--------------|----|-------------------|------------|
| ✓ A177 | 2005-0032734 | A1 | Davis et al. | 02-10-2005 |
| ✓ A178 | 2005-0032736 | A1 | Krieg et al. | 02-10-2005 |
| ✓ A179 | 2005-0037403 | A1 | Krieg et al. | 02-17-2005 |
| ✓ A180 | 2005-0037985 | A1 | Krieg et al. | 02-17-2005 |
| ✓ A181 | 2005-0043529 | A1 | Davis et al. | 02-24-2005 |
| ✓ A182 | 2005-0049215 | A1 | Krieg et al. | 03-03-2005 |
| ✓ A183 | 2005-0049216 | A1 | Krieg et al. | 03-03-2005 |
| ✓ A184 | 2005-0054601 | A1 | Wagner et al. | 03-10-2005 |
| ✓ A185 | 2005-0054602 | A1 | Krieg et al. | 03-10-2005 |
| ✓ A186 | 2005-0059619 | A1 | Krieg et al. | 03-17-2005 |
| ✓ A187 | 2005-0059625 | A1 | Krieg et al. | 03-17-2005 |
| ✓ A188 | 2005-0070491 | A1 | Krieg et al. | 03-31-2005 |
| ✓ A189 | 2005-0075302 | A1 | Hutcherson et al. | 04-07-2005 |
| ✓ A190 | 2005-0100983 | A1 | Bauer et al. | 05-12-2005 |
| ✓ A191 | 2005-0101554 | A1 | Krieg et al. | 05-12-2005 |
| ✓ A192 | 2005-0101557 | A1 | Krieg et al. | 05-12-2005 |
| ✓ A193 | 2005-0119273 | A1 | Lipford et al. | 06-02-2005 |
| ✓ A194 | 2005-0123523 | A1 | Krieg et al. | 06-09-2005 |
| ✓ A195 | 2005-0130911 | A1 | Uhlmann et al. | 06-16-2005 |
| ✓ A196 | 2005-0148537 | A1 | Krieg et al. | 07-07-2005 |
| ✓ A197 | 2005-0169888 | A1 | Hartman et al. | 08-04-2005 |
| ✓ A198 | 2005-0171047 | A1 | Krieg et al. | 08-04-2005 |
| ✓ A199 | 2005-0176672 | A1 | Scheule et al. | 08-11-2005 |
| ✓ A200 | 2005-0181422 | A1 | Bauer et al. | 08-18-2005 |
| ✓ A201 | 2005-0182017 | A1 | Krieg | 08-18-2005 |
| ✓ A202 | 2005-0191342 | A1 | Tam et al. | 09-01-2005 |
| ✓ A203 | 2005-0197314 | A1 | Krieg et al. | 09-08-2005 |
| ✓ A204 | 2005-0209184 | A1 | Klinman et al. | 09-22-2005 |
| ✓ A205 | 2005-0214355 | A1 | Klinman et al. | 09-29-2005 |
| ✓ A206 | 2005-0215501 | A1 | Lipford et al. | 09-29-2005 |
| ✓ A207 | 2005-0233995 | A1 | Krieg et al. | 10-20-2005 |
| ✓ A208 | 2005-0233999 | A1 | Krieg et al. | 10-20-2005 |
| ✓ A209 | 2005-0239732 | A1 | Krieg et al. | 10-27-2005 |
| ✓ A210 | 2005-0239733 | A1 | Jurk et al. | 10-27-2005 |
| ✓ A211 | 2005-0239734 | A1 | Uhlmann et al. | 10-27-2005 |
| ✓ A212 | 2005-0239736 | A1 | Krieg et al. | 10-27-2005 |

| | |
|---|------------------|
| EXAMINER: | DATE CONSIDERED: |
|  | 12/24/07 |

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

| | | | | | |
|--|---|----|----|--------------------------------|-----------------------------------|
| FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT | | | | APPLICATION NO.: 10/023,909 | ATTY. DOCKET NO.: C1039.70058US00 |
| | | | | FILING DATE: December 18, 2001 | CONFIRMATION NO.: 8458 |
| | | | | APPLICANT: Davis et al. | |
| | | | | GROUP ART UNIT: 1648 | EXAMINER: Jeffrey S. Parkin |
| Sheet | 4 | of | 12 | | |

| | | | | | |
|---|------|--------------|----|------------------|------------|
| ✓ | A213 | 2005-0244379 | A1 | Krieg et al. | 11-03-2005 |
| ✓ | A214 | 2005-0244380 | A1 | Krieg et al. | 11-03-2005 |
| ✓ | A215 | 2005-0245477 | A1 | Krieg et al. | 11-03-2005 |
| ✓ | A216 | 2005-0249794 | A1 | Semple et al. | 11-10-2005 |
| ✓ | A217 | 2005-0250726 | A1 | Krieg et al. | 11-10-2005 |
| ✓ | A218 | 2005-0256073 | A1 | Lipford et al. | 11-17-2005 |
| ✓ | A219 | 2005-0267064 | A1 | Krieg et al. | 12-01-2005 |
| ✓ | A220 | 2005-0277604 | A1 | Krieg et al. | 12-15-2005 |
| ✓ | A221 | 2005-0277609 | A1 | Krieg et al. | 12-15-2005 |
| ✓ | A222 | 2006-0003955 | A1 | Krieg et al. | 01-05-2006 |
| ✓ | A223 | 2006-0003962 | A1 | Ahluwalia et al. | 01-05-2006 |
| ✓ | A224 | 2006-0019916 | A1 | Krieg et al. | 01-26-2006 |
| ✓ | A225 | 2006-0019923 | A1 | Davis et al. | 01-26-2006 |
| ✓ | A226 | 2006-0058251 | A1 | Krieg et al. | 03-16-2006 |
| ✓ | A227 | 2006-0089326 | A1 | Krieg et al. | 04-27-2006 |
| ✓ | A228 | 2006-0094683 | A1 | Krieg et al. | 05-04-2006 |
| ✓ | A229 | 2006-0140875 | A1 | Krieg et al. | 06-29-2006 |
| ✓ | A230 | 2006-0154890 | A1 | Bratzler et al. | 07-13-2006 |
| ✓ | A231 | 2006-0172966 | A1 | Lipford et al. | 08-03-2006 |
| ✓ | A232 | 2006-0188913 | A1 | Krieg et al. | 08-24-2006 |
| ✓ | A233 | 2006-0211639 | A1 | Bratzler et al. | 09-21-2006 |
| ✓ | A234 | 2006-0211644 | A1 | Krieg et al. | 09-21-2006 |
| ✓ | A235 | 2006-0223769 | A1 | Dow et al. | 10-05-2006 |
| ✓ | A236 | 2006-0229271 | A1 | Krieg et al. | 10-12-2006 |
| ✓ | A237 | 2006-0241076 | A1 | Uhlmann et al. | 10-26-2006 |
| ✓ | A238 | 2006-0246035 | A1 | Ahluwalia et al. | 11-02-2006 |
| ✓ | A239 | 2006-0251623 | A1 | Bachmann et al. | 11-09-2006 |
| ✓ | A240 | 2006-0251677 | A1 | Bachmann et al. | 11-09-2006 |
| ✓ | A241 | 2006-0286070 | A1 | Hartmann et al. | 12-21-2006 |
| ✓ | A242 | 2006-0287263 | A1 | Davis et al. | 12-21-2006 |
| ✓ | A243 | 2007-0009482 | A1 | Krieg et al. | 01-11-2007 |
| ✓ | A244 | 2007-0010470 | A1 | Krieg et al. | 01-11-2007 |
| ✓ | A245 | 2007-0037767 | A1 | Bratzler et al. | 02-15-2007 |
| ✓ | A246 | 2007-0065467 | A1 | Krieg et al. | 03-22-2007 |
| ✓ | A247 | 2007-0066553 | A1 | Krieg et al. | 03-22-2007 |
| ✓ | A248 | 2007-0066554 | A1 | Krieg et al. | 03-22-2007 |

| | |
|-----------|------------------|
| EXAMINER: | DATE CONSIDERED: |
| | |

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

| | | | | | | | |
|---|---|----|----|--------------------------------|-----------------------------------|-----------------------------|--|
| FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT | | | | APPLICATION NO.: 10/023,909 | ATTY. DOCKET NO.: C1039.70058US00 | | |
| | | | | FILING DATE: December 18, 2001 | CONFIRMATION NO.: 8458 | | |
| | | | | APPLICANT: Davis et al. | | | |
| | | | | GROUP ART UNIT: 1648 | | EXAMINER: Jeffrey S. Parkin | |
| Sheet | 5 | of | 12 | | | | |


| | | | | | |
|---|------|--------------|----|-----------------|------------|
| ✓ | A249 | 2007-0078104 | A1 | Krieg et al. | 04-05-2007 |
| ↓ | A250 | 2007-0129320 | A9 | Davis et al. | 06-07-2007 |
| ↓ | A251 | 2007-0142315 | A1 | Forsbach et al. | 06-21-2007 |
| ↓ | A252 | 2007-0184465 | A1 | Wagner et al. | 08-09-2007 |
| ↓ | A253 | 2007-0202128 | A1 | Krieg et al. | 08-30-2007 |

FOREIGN PATENT DOCUMENTS

| Examiner's Initials # | Cite No. | Foreign Patent Document | | | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YYYY | Translation (Y/N) |
|-----------------------|----------|-------------------------|-------------|-----------|---|--|-------------------|
| | | Office/Country | Number | Kind Code | | | |
| ✓ | B27 | WO | 98/29557 | A1 | Biovector Therapeutics | 07-09-1998 | |
| ✓ | B28 | WO | 98/51278 | A2 | INEX Pharmaceuticals Corp. | 11-19-1998 | |
| ✓ | B29 | WO | 99/30686 | A1 | INEX Pharmaceuticals Corporation | 06-24-1999 | |
| ✓ | B30 | WO | 99/33493 | A1 | INEX Pharmaceuticals Corporation | 07-08-1999 | |
| ✓ | B31 | WO | 99/33868 | A2 | SmithKline Beecham Biologicals, S.A. | 07-08-1999 | |
| ✓ | B32 | WO | 99/43350 | A1 | IOMAI Corporation | 09-02-1999 | |
| ✓ | B33 | WO | 99/52549 | A1 | SmithKline Beecham Biologicals S.A. | 10-29-1999 | |
| ✓ | B34 | WO | 99/55743 | A1 | INEX Pharmaceuticals Corporation | 11-04-1999 | |
| ✓ | B35 | WO | 00/06588 | A1 | University of Iowa Research Foundation | 02-10-2000 | |
| ✓ | B36 | WO | 00/14217 | A2 | CPG Immunopharmaceuticals GMBH | 03-16-2000 | |
| ✓ | B37 | WO | 00/67023 | A1 | CPG Immunopharmaceuticals GMBH | 11-09-2000 | |
| ✓ | B38 | WO | 2004/026888 | A2 | Coley Pharmaceutical GMBH | 04-01-2004 | |
| ✓ | B39 | WO | 2004/094671 | A2 | Coley Pharmaceutical GMBH | 11-04-2004 | |
| ✓ | B40 | WO | 2006/080946 | A2 | Coley Pharmaceutical GMBH | 08-03-2006 | |
| ✓ | B41 | WO | 2007/031877 | A2 | Coley Pharmaceutical GMBH | 03-22-2007 | |
| ↓ | B42 | WO | 2007/038720 | A2 | Coley Pharmaceutical GMBH | 04-05-2007 | |

OTHER ART – NON PATENT LITERATURE DOCUMENTS


| Examiner's Initials # | Cite No. | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | Translation (Y/N) |
|-----------------------|----------|---|-------------------|
| ✓ | C26 | Press Release, January 2007, "Coley Pharmaceutical Group Updates Hepatitis C Drug Development Strategy". | |
| ✓ | C27 | Press Release, June 2007, "Coley Pharmaceutical Group Announces Pfizer's Discontinuation of Clinical Trials for PF-3512676 Combined with Cytotoxic Chemotherapy in Advanced Non Small Cell Lung Cancer". | |

| | |
|---|------------------|
| EXAMINER: | DATE CONSIDERED: |
|  12/24/07 | |

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

| | | | | | |
|--|---|----|----|--------------------------------|-----------------------------------|
| FORM PTO-1449/A and B (modified PTO/SB/08) | | | | APPLICATION NO.: 10/023,909 | ATTY. DOCKET NO.: C1039.70058US00 |
| | | | | FILING DATE: December 18, 2001 | CONFIRMATION NO.: 8458 |
| | | | | APPLICANT: Davis et al. | |
| Sheet | 6 | of | 12 | GROUP ART UNIT: 1648 | EXAMINER: Jeffrey S. Parkin |


| | | | |
|---|-----|--|--|
| | C28 | AGRAWAL et al., Pharmacokinetics of antisense oligonucleotides. Clin Pharmacokinet. 1995 Jan;28(1):7-16. | |
| | C29 | AGRAWAL et al., Chapter 19: Pharmacokinetics and bioavailability of antisense oligonucleotides following oral and colorectal administrations in experimental animals. 1998; 525-43. | |
| | C30 | AGRAWAL et al., Antisense oligonucleotides: towards clinical trials. Trends in Biotechnology, 1996; 14: 376-87. | |
| | C31 | ALPAR et al., Potential of particulate carriers for the mucosal delivery of DNA vaccines. Biochem Soc Trans. 1997 May;25(2):337S. | |
| | C32 | ANITESCU et al., Interleukin-10 functions in vitro and in vivo to inhibit bacterial DNA-induced secretion of interleukin-12. J Interferon Cytokine Res. 1997 Dec;17(12):781-8. | |
| | C33 | BAUER et al., DNA activates human immune cells through a CpG sequence-dependent manner. Immunology. 1999 Aug;97(4):699-705. | |
| | C34 | BENNETT, Intracellular delivery of oligonucleotides with cationic liposomes. In: Delivery Strategies for Antisense Oligonucleotide Therapeutics. Akhtar, Ed. 1995:223-32. | |
| | C35 | BOWERSOCK et al., Evaluation of an orally administered vaccine, using hydrogels containing bacterial exotoxins of <i>Pasteurella haemolytica</i> , in cattle. Am J Vet Res. 1994 Apr;55(4):502-9. | |
| | C36 | BRAZOLOT MILLAN et al., CpG DNA can induce strong Th1 humoral and cell-mediated immune responses against hepatitis B surface antigen in young mice. Proc Natl Acad Sci U S A. 1998 Dec 22;95(26):15553-8. | |
| | C37 | BROIDE et al., DNA-Based immunization for asthma. Int Arch Allergy Immunol. 1999 Feb-Apr;118(2-4):453-6. | |
| | C38 | CARSON et al., Oligonucleotide adjuvants for T helper 1 (Th1)-specific vaccination. J Exp Med. 1997 Nov 17;186(10):1621-2. | |
| | C39 | CHACE et al., Bacterial DNA-induced NK cell IFN-gamma production is dependent on macrophage secretion of IL-12. Clin Immunol Immunopathol. 1997 Aug;84(2):185-93. | |
| | C40 | CHELVARAJAN et al., CpG oligodeoxynucleotides overcome the unresponsiveness of neonatal B cells to stimulation with the thymus-independent stimuli anti-IgM and TNP-Ficoll. Eur J Immunol. 1999 Sep;29(9):2808-18. | |
| | C41 | CHEN et al., Protective immunity induced by oral immunization with a rotavirus DNA vaccine encapsulated in microparticles. J Virol. 1998 Jul;72(7):5757-61. | |
| | C42 | CHU et al., CpG oligodeoxynucleotides down-regulate macrophage class II MHC antigen processing. J Immunol. 1999 Aug 1;163(3):1188-94. | |
| | C43 | CROOKE et al., Phosphorothioate Oligonucleotides. Therapeut Apps. 1995;ch5:63-84. | |
| | C44 | CRYZ et al., European Commission COST/STD Initiative. Report of the expert panel VII. Vaccine delivery systems. Vaccine. 1996 May;14(7):665-90. | |
| | C45 | DAVIS et al., DNA vaccines for prophylactic or therapeutic immunization against hepatitis B virus. Mt Sinai J Med. 1999 Mar;66(2):84-90. Review. | |
| | C46 | DELONG et al., Characterization of complexes of oligonucleotides with polyamidoamine starburst dendrimers and effects on intracellular delivery. J Pharm Sci. 1997 Jun;86(6):762-4. Abstract Only. | |
| | C47 | ELDRIDGE et al., Biodegradable microspheres as a vaccine delivery system. Mol Immunol. 1991 Mar;28(3):287-94. Abstract Only. | |
| ↓ | C48 | EMI et al., Gene transfer mediated by polyarginine requires a formation of big carrier-complex of DNA aggregate. Biochem Biophys Res Commun. 1997 Feb 13;231(2):421-4. | |

| | |
|---|------------------|
| EXAMINER: | DATE CONSIDERED: |
|  | 12/24/07 |

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

| | | | | | |
|--|---|----|----|--------------------------------|-----------------------------------|
| FORM PTO-1449/A and B (modified PTO/SB/08) | | | | APPLICATION NO.: 10/023,909 | ATTY. DOCKET NO.: C1039.70058US00 |
| | | | | FILING DATE: December 18, 2001 | CONFIRMATION NO.: 8458 |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT | | | | APPLICANT: Davis et al. | |
| | | | | GROUP ART UNIT: 1648 | EXAMINER: Jeffrey S. Parkin |
| Sheet | 7 | of | 12 | | |


| | | | |
|---|-----|--|--|
| ✓ | C49 | ETCHART et al., Class I-restricted CTL induction by mucosal immunization with naked DNA encoding measles virus haemagglutinin. J Gen Virol. 1997 Jul;78 (Pt 7):1577-80. | |
| ✓ | C50 | FILION et al., Major limitations in the use of cationic liposomes for DNA delivery. Int J Pharmaceut. 1998; 162:159-70. | |
| ✓ | C51 | FRALEY et al., New generation liposomes: the engineering of an efficient vehicle for intracellular delivery of nucleic acids. Trends Biochem Sci. 1981;6:77-80. | |
| ✓ | C52 | GALLICHAN et al., Specific secretory immune responses in the female genital tract following intranasal immunization with a recombinant adenovirus expressing glycoprotein B of herpes simplex virus. Vaccine. 1995 Nov;13(16):1589-95. | |
| ✓ | C53 | GEISSLER et al., Enhancement of cellular and humoral immune responses to hepatitis C virus core protein using DNA-based vaccines augmented with cytokine-expressing plasmids. J Immunol. 1997 Feb 1;158(3):1231-7. | |
| ✓ | C54 | GRAMZINSKI et al., Immune response to a hepatitis B DNA vaccine in Aotus monkeys: a comparison of vaccine formulation, route, and method of administration. Mol Med. 1998 Feb;4(2):109-18. | |
| ✓ | C55 | GREGORIADIS et al., Liposomes for drugs and vaccines. Trends Biotechnol. 1985;3:235-41. | |
| ✓ | C56 | GREGORIADIS et al., Engineering liposomes for drug delivery: progress and problems. Trends Biotechnol. 1995 Dec;13(12):527-37. | |
| ✓ | C57 | HANEBERG et al., Induction of specific immunoglobulin A in the small intestine, colon-rectum, and vagina measured by a new method for collection of secretions from local mucosal surfaces. Infect Immun. 1994 Jan;62(1):15-23. | |
| ✓ | C58 | HARTMANN et al., CpG DNA and LPS induce distinct patterns of activation in human monocytes. Gene Ther. 1999 May;6(5):893-903. | |
| ✓ | C59 | HARTMANN et al., Spontaneous and cationic lipid-mediated uptake of antisense oligonucleotides in human monocytes and lymphocytes. J Pharmacol Exp Ther. 1998 May;285(2):920-8. | |
| ✓ | C60 | HARTMANN et al., CpG DNA: a potent signal for growth, activation, and maturation of human dendritic cells. Proc Natl Acad Sci U S A. 1999 Aug 3;96(16):9305-10. | |
| ✓ | C61 | HAYNES et al., Particle-mediated nucleic acid immunization. J Biotechnol. 1996 Jan 26;44(1-3):37-42. | |
| ✓ | C62 | HEDLEY et al., Microspheres containing plasmid-encoded antigens elicit cytotoxic T-cell responses. Nat Med. 1998 Mar;4(3):365-8. | |
| ✓ | C63 | HOLMGREN et al., Cholera toxin and cholera B subunit as oral-mucosal adjuvant and antigen vector systems. Vaccine. 1993 Sep;11(12):1179-84. | |
| ✓ | C64 | HOPKIN et al., Curbing the CpGs of Bacterial and Viral DNA. BioMedNet. 1999 Jun25; Issue 57. | |
| ✓ | C65 | HORNQUIST et al., Cholera toxin adjuvant greatly promotes antigen priming of T cells. Eur J Immunol. 1993 Sep;23(9):2136-43. | |
| ✓ | C66 | HUANG et al., Induction and regulation of Th1-inducing cytokines by bacterial DNA, lipopolysaccharide, and heat-inactivated bacteria. Infect Immun. 1999 Dec;67(12):6257-63. | |
| ✓ | C67 | HUDSON et al., Nucleic acid dendrimers: Novel biopolymer structures. J Am Chem Soc. 1993;115:2119-24. | |

| | |
|---|------------------|
| EXAMINER: | DATE CONSIDERED: |
|  | 12/24/07 |

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

| | | | | | |
|--|---|----|----|--------------------------------|-----------------------------------|
| FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT | | | | APPLICATION NO.: 10/023,909 | ATTY. DOCKET NO.: C1039.70058US00 |
| | | | | FILING DATE: December 18, 2001 | CONFIRMATION NO.: 8458 |
| | | | | APPLICANT: Davis et al. | |
| | | | | GROUP ART UNIT: 1648 | EXAMINER: Jeffrey S. Parkin |
| Sheet | 8 | of | 12 | | |


| | | | |
|---|-----|--|--|
| ✓ | C68 | IHO et al., Oligodeoxynucleotides containing palindrome sequences with internal 5'-CpG-3' act directly on human NK and activated T cells to induce IFN-gamma production in vitro. J Immunol. 1999 Oct 1;163(7):3642-52. | |
| ✓ | C69 | JAKOB et al., Activation of cutaneous dendritic cells by CpG-containing oligodeoxynucleotides: a role for dendritic cells in the augmentation of Th1 responses by immunostimulatory DNA. J Immunol. 1998 Sep 15;161(6):3042-9. | |
| ✓ | C70 | JAKOB et al., Bacterial DNA and CpG-containing oligodeoxynucleotides activate cutaneous dendritic cells and induce IL-12 production: implications for the augmentation of Th1 responses. Int Arch Allergy Immunol. 1999 Feb-Apr;118(2-4):457-61. | |
| ✓ | C71 | JONES et al., Poly(DL-lactide-co-glycolide)-encapsulated plasmid DNA elicits systemic and mucosal antibody responses to encoded protein after oral administration. Vaccine. 1997 Jun;15(8):814-7. | |
| ✓ | C72 | JONES et al., Synthetic oligodeoxynucleotides containing CpG motifs enhance immunogenicity of a peptide malaria vaccine in Aotus monkeys. Vaccine. 1999 Aug 6;17(23-24):3065-71. | |
| ✓ | C73 | KATAOKA et al., Immunotherapeutic potential in guinea-pig tumor model of deoxyribonucleic acid from Mycobacterium bovis BCG complexed with poly-L-lysine and carboxymethylcellulose. Jpn J Med Sci Biol. 1990 Oct;43(5):171-82. | |
| ✓ | C74 | KLINMAN et al., Therapeutic applications of CpG-containing oligodeoxynucleotides. Antisense Nucleic Acid Drug Dev. 1998 Apr;8(2):181-4. | |
| ✓ | C75 | KLINMAN et al., CpG motifs as immune adjuvants. Vaccine. 1999 Jan;17(1):19-25. | |
| ✓ | C76 | KRIEG et al., Lymphocyte activation mediated by oligodeoxynucleotides or DNA containing novel un-methylated CpG motifs. American College of Rheumatology 58 th National Scientific Meeting. Minneapolis, Minnesota, October 22, 1994. Abstracts. Arthritis Rheum. 1994 Sep;37(9 Suppl). | |
| ✓ | C77 | KRIEG et al., Direct immunologic activities of CpG DNA and implications for gene therapy. J Gene Med. 1999 Jan-Feb;1(1):56-63. | |
| ✓ | C78 | KRIEG et al., Applications of immune stimulatory CpG DNA for antigen-specific and antigen-nonspecific cancer immunotherapy. Eur J Canc. 1999 Oct; 35/Suppl 4:S10. Abstract #14. | |
| ✓ | C79 | KRIEG et al., Chapter 8: Immune Stimulation by Oligonucleotides. In: Antisense Research and Application. Crooke, Ed. 1998:243-62. | |
| ✓ | C80 | KRIEG et al., Bacterial DNA or oligonucleotides containing CpG motifs protect mice from lethal L. monocytogenes challenge. 1996 Meeting on Molecular Approaches to the Control of Infectious Diseases. Cold Spring Harbor Laboratory, September 9-13, 1996:116. | |
| ✓ | C81 | KRIEG et al., Mechanisms and applications of immune stimulatory CpG oligodeoxynucleotides. Biochim Biophys Acta. 1999 Dec 10;1489(1):107-16. | |
| ✓ | C82 | KRIEG et al., The CpG motif: Implications for clinical immunology. BioDrugs. 1998 Nov 1;10(5):341-6. | |
| ✓ | C83 | KRIEG et al., Mechanism of action of CpG DNA. Curr Top Microbiol Immunol. 2000;247:1-21. | |
| ✓ | C84 | KRIEG et al., Mechanisms and therapeutic applications of immune stimulatory CpG DNA. Pharmacol Ther. 1999 Nov;84(2):113-20. | |
| ✓ | C85 | KRIEG et al., Sequence motifs in adenoviral DNA block immune activation by stimulatory CpG motifs. Proc Natl Acad Sci U S A. 1998 Oct 13;95(21):12631-6. | |
| ✓ | C86 | KRIEG et al., CpG DNA: a novel immunomodulator. Trends Microbiol. 1999 Feb;7(2):64-5. | |
| ✓ | C87 | KRIEG et al., Infection. In: McGraw Hill Book. 1996:242-3. | |

| | |
|---|------------------|
| EXAMINER: | DATE CONSIDERED: |
|  | 12/24/02 |

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

| | | | | | |
|--|---|----|----|--------------------------------|-----------------------------------|
| FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT | | | | APPLICATION NO.: 10/023,909 | ATTY. DOCKET NO.: C1039.70058US00 |
| | | | | FILING DATE: December 18, 2001 | CONFIRMATION NO.: 8458 |
| | | | | APPLICANT: Davis et al. | |
| | | | | GROUP ART UNIT: 1648 | EXAMINER: Jeffrey S. Parkin |
| Sheet | 9 | of | 12 | | |


| | | | |
|---|------|---|--|
| J | C88 | KRIEG et al., Lymphocyte activation by CpG dinucleotide motifs in prokaryotic DNA. Trends Microbiol. 1996 Feb;4(2):73-6. | |
| J | C89 | KRIEG, Therapeutic potential of Toll-like receptor 9 activation. Nat Rev Drug Discov. 2006 Jun;5(6):471-84. | |
| | C90 | KUKOWSKA-LATALLO et al., Efficient transfer of genetic material into mammalian cells using Starburst polyamidoamine dendrimers. Proc Natl Acad Sci U S A. 1996 May 14;93(10):4897-902. | |
| | C91 | KURAMOTO et al., Induction of T-cell-mediated immunity against MethA fibrosarcoma by intratumoral injections of a bacillus Calmette-Guerin nucleic acid fraction. Cancer Immunol Immunother. 1992;34(5):283-8. | |
| | C92 | KURAMOTO et al., Changes of host cell infiltration into Meth A fibrosarcoma tumor during the course of regression induced by injections of a BCG nucleic acid fraction. Int J Immunopharmacol. 1992 Jul;14(5):773-82. | |
| | C93 | KURAMOTO et al., In situ infiltration of natural killer-like cells induced by intradermal injection of the nucleic acid fraction from BCG. Microbiol Immunol. 1989;33(11):929-40. | |
| | C94 | LeCLERC et al., The preferential induction of a Th1 immune response by DNA-based immunization is mediated by the immunostimulatory effect of plasmid DNA. Cell Immunol. 1997 Aug 1;179(2):97-106. | |
| | C95 | LEE et al., Immuno-stimulatory effects of bacterial-derived plasmids depend on the nature of the antigen in intramuscular DNA inoculations. Immunology. 1998 Jul;94(3):285-9. | |
| | C96 | LETSINGER et al., Cholestryl-conjugated oligonucleotides: synthesis, properties, and activity as inhibitors of replication of human immunodeficiency virus in cell culture. Proc Natl Acad Sci U S A. 1989 Sep;86(17):6553-6. | |
| | C97 | LETSINGER et al., Synthesis and properties of modified oligonucleotides. Nucleic Acids Symp Ser. 1991;(24):75-8. | |
| | C98 | LIPFORD et al., CpG-containing synthetic oligonucleotides promote B and cytotoxic T cell responses to protein antigen: a new class of vaccine adjuvants. Eur J Immunol. 1997 Sep;27(9):2340-4. | |
| | C99 | LITZINGER et al., Fate of cationic liposomes and their complex with oligonucleotide in vivo. Biochim Biophys Acta. 1996 Jun 11;1281(2):139-49. | |
| | C100 | LIU et al., Immunostimulatory CpG oligodeoxynucleotides enhance the immune response to vaccine strategies involving granulocyte-macrophage colony-stimulating factor. Blood. 1998 Nov 15;92(10):3730-6. | |
| | C101 | LIU et al., CpG ODN is an effective adjuvant in immunization with tumor antigen. J Invest Med. 1997 Sept;45(7):333A. | |
| | C102 | LIU et al., Immunization of non-human primates with DNA vaccines. Vaccine. 1997 Jun;15(8):909-12. | |
| | C103 | MacGREGOR et al., First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: safety and host response. J Infect Dis. 1998 Jul;178(1):92-100. | |
| | C104 | MALOY et al., Induction of Th1 and Th2 CD4+ T cell responses by oral or parenteral immunization with ISCOMS. Eur J Immunol. 1995 Oct;25(10):2835-41. | |
| ↓ | C105 | MARTIN-OROZCO et al., Enhancement of antigen-presenting cell surface molecules involved in cognate interactions by immunostimulatory DNA sequences. Int Immunol. 1999 Jul;11(7):1111-8. | |

| | |
|---|------------------|
| EXAMINER: | DATE CONSIDERED: |
|  | 12/24/07 |

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

| | | | | | |
|--|----|----|----|--------------------------------|-----------------------------------|
| FORM PTO-1449/A and B (modified PTO/SB/08) | | | | APPLICATION NO.: 10/023,909 | ATTY. DOCKET NO.: C1039.70058US00 |
| | | | | FILING DATE: December 18, 2001 | CONFIRMATION NO.: 8458 |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT | | | | APPLICANT: Davis et al. | |
| | | | | GROUP ART UNIT: 1648 | |
| Sheet | 10 | of | 12 | EXAMINER: | Jeffrey S. Parkin |


| | | | |
|---|------|--|--|
| | C106 | McCLUSKIE et al., CpG DNA as mucosal adjuvant. Immunol Letts. 1999;69(1):30-1. Abstract #5.2 | |
| | C107 | McCLUSKIE et al., Novel strategies using DNA for the induction of mucosal immunity. Crit Rev Immunol. 1999;19(4):303-29. | |
| | C108 | McCLUSKIE et al., Immunization against hepatitis B virus by mucosal administration of antigen-antibody complexes. Viral Immunol. 1998;11(4):245-52. | |
| | C109 | McCLUSKIE et al., Route and method of delivery of DNA vaccine influence immune responses in mice and non-human primates. Mol Med. 1999 May;5(5):287-300. | |
| | C110 | McCLUSKIE et al., Mucosal immunization with DNA vaccines. Microbes Infect. 1999 Jul;1(9):685-98. | |
| | C111 | McGHEE et al., The mucosal immune system: from fundamental concepts to vaccine development. Vaccine. 1992;10(2):75-88. | |
| | C112 | OKADA et al., Bone marrow-derived dendritic cells pulsed with a tumor-specific peptide elicit effective anti-tumor immunity against intracranial neoplasms. Int J Cancer. 1998 Oct 5;78(2):196-201. | |
| | C113 | OXENIUS et al., CpG-containing oligonucleotides are efficient adjuvants for induction of protective antiviral immune responses with T-cell peptide vaccines. J Virol. 1999 May;73(5):4120-6. | |
| | C114 | PISETSKY et al., Immunological properties of bacterial DNA. Ann N Y Acad Sci. 1995 Nov 27;772:152-63. | |
| | C115 | PISETSKY, The influence of base sequence on the immunostimulatory properties of DNA. Immunol Res. 1999;19(1):35-46. | |
| | C116 | PISETSKY et al., Immune activation by bacterial DNA: a new genetic code. Immunity. 1996 Oct;5(4):303-10. | |
| | C117 | PISETSKY et al., The influence of base sequence on the immunological properties of defined oligonucleotides. Immunopharmacology. 1998 Nov;40(3):199-208. | |
| | C118 | ROBERTSON et al., Crohn's trial shows the pros of antisense. Nat Biotechnol. 1997 Mar;15(3):209. | |
| | C119 | ROBINSON, Nucleic acid vaccines: an overview. Vaccine. 1997 Jun;15(8):785-7. | |
| | C120 | SANDS et al., Biodistribution and metabolism of internally 3H-labeled oligonucleotides. I. Comparison of a phosphodiester and a phosphorothioate. Mol Pharmacol. 1994 May;45(5):932-43. | |
| | C121 | SCHWARTZ et al., Bacterial DNA or oligonucleotides containing unmethylated CpG motifs can minimize lipopolysaccharide-induced inflammation in the lower respiratory tract through an IL-12-dependent pathway. J Immunol. 1999 Jul 1;163(1):224-31. | |
| | C122 | SIDMAN et al., Gamma-interferon is one of several direct B cell-maturing lymphokines. Nature. 1984 Jun 28-Jul 4;309(5971):801-4. | |
| | C123 | SONEHARA et al., Hexamer palindromic oligonucleotides with 5'-CG-3' motif(s) induce production of interferon. J Interferon Cytokine Res. 1996 Oct;16(10):799-803. | |
| | C124 | SPARWASSER et al., Bacterial DNA causes septic shock. Nature. 1997 Mar 27;386(6623):336-7. | |
| | C125 | SPARWASSER et al., Bacterial DNA and immunostimulatory CpG oligonucleotides trigger maturation and activation of murine dendritic cells. Eur J Immunol. 1998 Jun;28(6):2045-54. | |
| ↓ | C126 | SPARWASSER et al., Immunostimulatory CpG-oligodeoxynucleotides cause extramedullary murine hemopoiesis. J Immunol. 1999 Feb 15;162(4):2368-74. | |

| | |
|---|------------------|
| EXAMINER: | DATE CONSIDERED: |
|  | 12/24/07 |

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.


| | | | | | |
|--|--|--|--|--------------------------------|-----------------------------------|
| FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT | | | | APPLICATION NO.: 10/023,909 | ATTY. DOCKET NO.: C1039.70058US00 |
| | | | | FILING DATE: December 18, 2001 | CONFIRMATION NO.: 8458 |
| | | | | APPLICANT: Davis et al. | |
| | | | | GROUP ART UNIT: 1648 | EXAMINER: Jeffrey S. Parkin |
| Sheet 11 of 12 | | | | | |

| | | | |
|---|------|---|--|
| J | C127 | STAATS et al., Mucosal immunity to infection with implications for vaccine development. <i>Curr Opin Immunol.</i> 1994 Aug;6(4):572-83. | |
| | C128 | STEIN et al., Problems in interpretation of data derived from in vitro and in vivo use of antisense oligodeoxynucleotides. <i>Antisense Res Dev.</i> 1994 Summer;4(2):67-9. | |
| | C129 | STEIN et al., Non-antisense effects of oligodeoxynucleotides. <i>Antisense Technology.</i> 1997; ch11: 241-64. | |
| | C130 | SUN et al. Type I interferon-mediated stimulation of T cells by CpG DNA. <i>J Exp Med.</i> 1998 Dec 21;188(12):2335-42. | |
| | C131 | SUN et al., DNA as an adjuvant: capacity of insect DNA and synthetic oligodeoxynucleotides to augment T cell responses to specific antigen. <i>Exp Med.</i> 1998 Apr 6;187(7):1145-50. | |
| | C132 | TACKET et al., Phase I safety and immune response studies of a DNA vaccine encoding hepatitis B surface antigen delivered by a gene delivery device. <i>Vaccine.</i> 1999 Jul 16;17(22):2826-9. | |
| | C133 | TOKUNAGA et al., Synthetic oligonucleotides with particular base sequences from the cDNA encoding proteins of <i>Mycobacterium bovis</i> BCG induce interferons and activate natural killer cells. <i>Microbiol Immunol.</i> 1992;36(1):55-66. | |
| | C134 | UGEN et al., DNA vaccination with HIV-1 expressing constructs elicits immune responses in humans. <i>Vaccine.</i> 1998 Nov;16(19):1818-21. | |
| | C135 | VLASOV et al., In Vivo pharmacokinetics of oligonucleotides following administration by different routes. CRC Press, Inc. Chapter 5. 1995:71-83. | |
| | C136 | WANG et al., Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine. <i>Science.</i> 1998 Oct 16;282(5388):476-80. | |
| | C137 | WEERATNA et al., Reduction of antigen expression from DNA vaccines by coadministered oligodeoxynucleotides. <i>Antisense Nucleic Acid Drug Dev.</i> 1998 Aug;8(4):351-6. | |
| | C138 | WEINER et al., Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization. <i>Proc Natl Acad Sci U S A.</i> 1997 Sep 30;94(20):10833-7. | |
| | C139 | WHALEN et al., DNA-mediated immunization to the hepatitis B surface antigen. Activation and entrainment of the immune response. <i>Ann N Y Acad Sci.</i> 1995 Nov 27;772:64-76. | |
| | C140 | WHITESELL et al., Stability, clearance, and disposition of intraventricularly administered oligodeoxynucleotides: implications for therapeutic application within the central nervous system. <i>Proc Natl Acad Sci U S A.</i> 1993 May 15;90(10):4665-9. | |
| | C141 | YEW et al., Contribution of plasmid DNA to inflammation in the lung after administration of cationic lipid:pDNA complexes. <i>Hum Gene Ther.</i> 1999 Jan 20;10:223-34. | |
| | C142 | YI et al. Rapid induction of mitogen-activated protein kinases by immune stimulatory CpG DNA. <i>J Immunol.</i> 1998 Nov 1;161(9):4493-7. | |
| | C143 | YI et al., CpG DNA rescue of murine B lymphoma cells from anti-IgM-induced growth arrest and programmed cell death is associated with increased expression of c-myc and bcl-xL. <i>J Immunol.</i> 1996 Dec 1;157(11):4918-25. | |
| | C144 | YI et al. CpG oligodeoxyribonucleotides rescue mature spleen B cells from spontaneous apoptosis and promote cell cycle entry. <i>J Immunol.</i> 1998 Jun 15;160(12):5898-906. | |
| ↓ | C145 | ZHAO et al., Pattern and kinetics of cytokine production following administration of phosphorothioate oligonucleotides in mice. <i>Antisense Nucleic Acid Drug Dev.</i> 1997 Oct;7(5):495-502. | |

| | |
|---|------------------|
| EXAMINER: | DATE CONSIDERED: |
|  | 12/24/07 |

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

| | | | | | |
|--|----|----|----|--------------------------------|-----------------------------------|
| FORM PTO-1449/A and B (modified PTO/SB/08) | | | | APPLICATION NO.: 10/023,909 | ATTY. DOCKET NO.: C1039.70058US00 |
| | | | | FILING DATE: December 18, 2001 | CONFIRMATION NO.: 8458 |
| | | | | APPLICANT: Davis et al. | |
| Sheet | 12 | of | 12 | GROUP ART UNIT: 1648 | EXAMINER: Jeffrey S. Parkin |

| | | | |
|--|------|--|--|
|  | C146 | ZHAO et al., Modulation of oligonucleotide-induced immune stimulation by cyclodextrin analogs. Biochem Pharmacol. 1996 Nov 22;52(10):1537-44. | |
|--|------|--|--|

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. ___, filed ___, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE – No copies of U.S. patents, published U.S. patent applications, or pending, unpublished patent applications stored in the USPTO's Image File Wrapper (IFW) system, are included. See 37 CFR §1.98 and 1287OG163. Copies of all other patent(s), publication(s), unpublished, pending U.S. patent applications, or other information listed are provided as required by 37 CFR §1.98 unless 1) such copies were provided in an IDS in an earlier application that complies with 37 CFR §1.98, and 2) the earlier application is relied upon for an earlier filing date under 35 U.S.C. §120.]

| | |
|---|------------------|
| EXAMINER: | DATE CONSIDERED: |
|  | 12/24/07 |

[#] EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.